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Summary 
Vigabatrin (gamma-vinyl GABA) is an irreversible inh:bitor of the enzyme GABA-transaminase 
(GABA-T) which is responsible for the catabolism of the major inhibitory neurotransmitter gamma-
aminobutyric acid (GABA) in the brain. Vigabatrin causes a several fold increase in the levels of brain 
GABA. The current study investigated further the effects of acute treatment with vigabatrin (100 mgl 
kg, i.p.) & phenobarbitone sodium (20 mg/kg, i.p.)f alone and in combination, in two rat behavioural 
models of exploratory activity: the elevated plus-maze model of anxiety and the open field test of 
locomotor activity. A single injection of vigabatrin or phenobarbitone alone, produced anxiolytic 
effects in the elevated plus-maze test and increased locomotor activity in the open field test. In contrast, 
after the concomitant administration of both drugs, the anxiolytic effects were no longer produced in 
the elevated plus-maze. The increased locomotor activity was also diminished in both tests of 
exploratory behaviour. These results shed light on the GABA hypothesis of anxiety, insofar as the 
increased availability of GABA, resulting from either GABA-T inhibition (vigabatrin) or facilitation of 
GABA-mediated chloride channels (phenobarbitone), seems to result in an increased emotional 
reactivity which, however, subsequently disappears during combined treatment. 
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Introductior: 
In the mammalian central nervous system (CNS), 
gamma-aminobutyric acid (GABA) is the major 
inhibitoryneurotransmitter1. Modulation ofGABA-
ergic activity can influence CNS events in a number 
of ways. Thus a reduction in GABA availability has 
been implicated in a variety of neurological and 
psychiatric disorders2 including epilepsy3, anxiety 
and depression4. In the brain, GABA is metabolised 
by a transamination reaction catalysed by the 
enzymeGABA-transaminase(E.C.2.6.1.19;GABA-
T) (for review, see Sherif, ~).Thus, agents capable 
of enhancing GABA-ergic inhibition via the GAB AA 
receptor have therapeutic uses as anxiolytics and 
anti-convulsants6. Vigabatrin (gamma-vinyl GABA) 
is a selective irreversible inhibitor of GABA-T7, 
causing a rapid dose-dependent increase in brain 
GABA levels8. Effective central inhibition ofGABA-
T was demonstrated following peripheral 
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admii1.istration ofvigabatrin7 9· Clinically, vigabatrin 
is demonstrated to have a consistent anticonvulsant 
effect in patients with chronic drug-resistant 
epilepsy10. 
Barbiturates belong to another class of drugs that 
are s:ill used in the management of grand-mal 
epilepsy11. Until the discovery ofbenzodiazepines 
in 1960s, barbiturates were the drugs of choice in 
the treatment of anxiety12. However, some 
barb:.turates (phenobarbitone) have specific 
anticonvulsant and anxiolytic effects, which do not 
seem to be a reflection of non-specific central 
nervous system depression, and these have a 
contbuing clinical use 12. There is a substantial 
evidmce of a specific interaction of barbiturates 
and the GABA system. Thus, barbiturates bind 
onto a specific recognition site on the GABAA 
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receptor chloride complex13. Stimulation Jf the 
barbiturate receptors leads to an increase in the 
binding of GABA to its receptor with a consequent 
increase in the inhibitory effect12. 
Previously, Sayin et al.14, Sherif and Oreland15 and 
Sherif et al.16 reported thatvigabatrinhas an anxiolytic-
like effect in the elevated plus-maze model of anxiety 
in rats. The elevated plus-maze model is basec. upon 
an unconditioned aversion to heights and open 
spaces17, and was validated for rodents18J 9• The 
validation of this test has also been reported in Pellow 
and File20, showing that it can detect the activity of 
non-benzodiazepines anxiolytics, and of several 
putative anxiogenic compounds. In a recent 
communication, pre-treatment with vigabatrin 
significantly potentiated the sleeping time of 
barbiturates in rats21. Therefore, the aim of this study 
was to further explore the interaction between 
vigabatrin and phenobarbitone on rat exploratory 
behaviour using the elevated plus-maze test and 
open-field behaviour. Doses of the compounds chosen 
forthepresentinvestigationhave been selected on the 
basis of the previous Studiesl6,21. 
Method 
Adult male albino Wistarrats weighing 302.0±22.9 
gram (Mean ± S.D.) at the beginning of the 
experiments were used in this study. They were 
inbred at the Central Animal Laboratory at the 
Medical University, Tripoli, Libya. The animals 
were housed in a standard laboratory cages (55 x 33 
x 20 cm), in a group of four per cage. They were 
maintained under a 12 h reversed light cycle (lights 
off 7.00 a.m.) in a temperature-contrJlled 
environment (22 ± 2°C). Rats were housed in these 
conditions for one week before behavioural testing. 
Food (pellets containing essential nutrients.) and 
tap-water were freely allowed. Measurements of 
exploratory behaviour have been conducted during 
the dark phase of the light cycle in a dimly 
illuminated laboratory between 10.00 a.m. and 1.00 
p.m. 
Vigabatrin (gamma-vinyl GABA) has been obtained 
from Astra-Pharmacia Pharmaceutical Company, 
Uppsala, Sweden, as a gift and phenobarbitone 
sodium was purchased from (BDH Chemicals Ltd 
Poole England). 
The elevated plus-maze apparatus was made 
of wood, consisted of two opposite open .:urns 
(50 x 10 cm) without side walls, and two 
opposite enclosed arms of the same size, with 
side walls and end wall (40 cm in height) The 
arms were connected from the central platform 
( 10 x 10 cm), forming the shape of a plus sign, 
and each arm was divided by lines into three 
equal squares15. The maze was elevated to a 
height of 50 cm from the ground. 
The open-field apparatus was a simple square 
arena (100 x 100 x 40 cm). The arena has 'ieen 
divided into 16 equal squares, thus allowing 
the observer to record: number of sq1:..ares 
visited and number of rearings, during a 4 
minute time periodls. 
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The rats were randomly assigned into four groups 
as follows: the control group received only 
physiological saline (i.p., n = 8), the phenobarbitone 
group received phenobarbitone sodium in a dose 
of 20 mg/kg (i.p., n = 8),30 minutes prior to testing, 
and the vigabatrin group received 100 mg/kg 
vigabatrin (i.p., n = 8), 3 hours prior to the testing, 
and the fourth group ( n = 8), was treated with 20 
mg/kg phenobarbitone sodium, 2.5 hours after 
vigabatrin pre-treatment ( 1~0 mg/kg, i.p.). Thirty 
minutes. later, the activity was recorded in the 
elevated plus-maze and open field apparatus. 
For measuring anxiolytic effects of the drugs in the 
elevated plus-maze, the animal was gently taken 
from the home cage and placed in the center of the 
plus-maze apparatus, with its head facing the closed 
arm, and observed for a period of 4 min. As 
traditionally employed, the key indices of anxiety 
in this test are the proportion of open arm entries 
and proportion oftime spent on the open arms19. The 
following parameters were recorded: time spent, 
number of squares crossed and number of entries 
into open and closed arms. The behavioural 
parameter was considered on a certain arm when 
the animal had placed all of its four feet on that arm. 
For measuring the locomotor activity in the open-
field test, the rat was gently placed (after the plus-
maze testing) in the center of the apparatus and 
observed for a period of 4 minutes. The apparatus 
can differentiate the vertical locomotor activity -
rearing activity from the horizontal locomotor 
activity - ambulatory activity (number of squares 
visited with all of its four feet on the square). 
Statistical analysis 
Analysis of variance (one-way ANOVA) and 
subsequent post-hoc analysis with the Fisher's PLSD 
test were performed in order to detect any difference 
between means of the control and individual groups. 
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Results 
In Table 1, analysis of the data by ANOV A revealed 
significant differences between the groups of rats, 
treated with phenobarbitone and vigabatrin alone, 
and in combination, in time spent on (F = 7.96; P < 
0.0001) and number of entries into (F = 3.45, P < 
0.05) open arms of the elevated plus-maze model of 
anxiety. Further analysis with the Fisher test 
indicated that treatment with a single dose of 
phenobarbitone sodium (20 mg/kg) produces a 
significant increase in the time spent on the open 
arms (P < 0.005) and a significant decrease in the 
time spent on the closed arms (P < 0.01) of the maze 
in comparison with control rats (Table 1). The single 
dose of vigabatrin ( 100 mg/kg) produced effects 
similar to that of phenobarbitone in increasing the 
time spent on open arms (P < 0.01) and in decreasing 
the time spent on closed arms (P < 0.005) of the 
maze. Similar observations have also been found in 
thenumberofopenarmentries(Table1). However, 
pre-treatment with vigabatrincompletely abolished 
the effect of phenobarbitone on the open and closed 
arms of the plus-maze. Thus, rats receiving both 
treatments showed no difference from the control 
group with regards to the time spent and number of 
entries into open and closed arms of the elevated 
plus-maze test (Table 1). The analysis of the data 
with ANOV A has also revealed significant changes 
in the percentage of time spent on open arms per 
total time (F = 7.51: P < 0.005) and in the number of 
open arm entries per total arm entries (F = 4.33; P < 
0.01) between the groups (Table 1). Further analysis 
with Fisher test indicated that the percentage of 
time spent on the open arms per total arms is 
signi£cantly increased in the groups of rats treated 
with phenobarbitone (P < 0.005) and vigabatrin (P < 
0.01 ) alone, however, with no change in the rats 
receiYing both treatments. With regard to the 
percentage of open arm entries per total entries, similar 
increases were observed after phenobarbitone (P < 
0.005) and after vigabatrin (P < 0.005) treatments, 
howe-.,rer, without a change in rats which received 
both treatments in comparison with control rats. 
The effects of the treatment with phenobarbitone 
and vigabatrin alone, and in combination, on line 
crossings on the arms of the maze are also shown in 
Table 1. Thus, significant changes in the line 
crossings on the open (F = 3.62; P < 0.05) and closed 
(F = 3.42; P < 0.05) arms of the elevated plus-maze 
test were found after the treatments. Further 
statis:ical analysis indicated a significant increase 
of these measures after treatment with 
phenobarbitone or vigabatrin in comparison with 
control group. However, pre-treatment with 
vigabatrin has abolished the effect of 
phenobarbitone (Table 1). The locomotor activities 
of rats, as calculated from the plus-maze data, for 
groups of phenobarbitone and vigabatrin alone 
andincombinationarealsogiven.Thus,asignificant 
difference in the total number of arm entries (F = 
3.44, P < 0.05) was observed. Treatment with 
phenobarbitone and vigabatrin alone significantly 
increased the total number of arm entries (P - 0.01 
and P < 0.01, respectively), however, rats which 
receiYed combined treatment did not show any 
significant difference from the control rats. 
Group Control Vigabatrin Phenobarbitone Vig. + Phenobarb. 
Time spent on 
open arms 11.3 ± 6.16 29.88 ± 5.76** 39.38 ± 5.52*** 10.25 ±4.42 
closed arms 200.87 ± 12.87 113.88 ± 12.57*** 145.75 ± 14.84** 192.63 ± 15.82 
Lines crossed on 
open arms 1.50 ± 0.96 4.5 ± 0.43** 6.38 ± 1.5** 2.38 ± 1.02 
closed arms 9.63 ± 2.61 15.88 ± 1.19* 19.50 ± 4.36* 9.13 ± 2.52 
No. of entries into 
open arms 1.63± 0.82 4.25 ± 0.53** 5.13 ± 0.74*** 2.25 ± 1.03 
closed arms 3.63±0.82 5.25 ±0.82 6.38 ± 1.73 3.25 ± 0.82 
Total no. of arm entries 
5.0 ± 1.65 9.5 ± 0.9E** 12.3 ± 2.72** 5.5 ± 1.68 
% time spent on open arms/total time 
5.9 ±3.6 21.7 ± 4.('** 23.0 ± 3.5*** 5.9 ± 2.8 
% open arm entries/total arm entries 
20.0 ±6.2 44.2 ± 2.8*** 45.6 ± 4.2*** 27.3 ± 9.2 
Data shown are means± S.E.M. *P < 0.05, **P < 0.01, ***P < 0.005 significantly different from the control. 
No statistically significant differences were found betv;een the -vig. + Phenobarb.-treated rats and control rats. 
Table 1: Effects of treatment with Phenobarbitone Sodium (20mg/kg, i.p.) and Vigabatrin (lOOmg/kg,i.p.) alone, and 
in combination on rat behaviour in the elevated plus-mcze model of anxiety. 
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In Figures 1 and 2, an analysis of the data with 
ANOVA has indicated significance differences 
between the treated groups in the number of squares 
visited (horizontal activity, F = 4.12, P < 0.01) and 
number of rearings (vertical activity, F = 7.45, P < 
0.005) in the open-field test. Phenobarbitone alone 
(20 mg/kg) was able to significantly increase the 
horizontal (P < 0.01) and vertical (P < 0.005) activities 
in comparison with control rats and rats treated 
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Control Phenobarbitone 
only with vigabatrin (100 mg/kg). There were, 
however, no significance differences between the 
control rats and rats treated with vigabatrin, with 
regard to the horizontal and vertical activities 
(Figures. 1 and 2). Pre-treatment of rats with 
vigabatrinhas completely abolished the stimulatory 
effect of phenobarbitone on the locomotor activity 
in the open field behaviour. 
Vigabatrin Vig. + Pheno. 
Figure 1: Effects of administration of phenobarbitone sodium (20mg/kg, i.p.) and vigabatrin (lOOmg/kg, i.p.) alone, 
and in combination on rat horizontal activity in the open-field test. Data are means ± S.E.M., **P < 0.01 
significantly different from the control group by :?isher's PLSD test. 
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Control Phenobarbitone Vigabatrin Vig. + Pheno. 
Figure 2: Effects of administration of phenobarbitone sodium (20mg/kg, i.p.) and vigabatrin (lOOmg/kg, i.p.) alone, 
and in combination· on rat vertical activity in the open-field test. Data are means± S.E.M., ***P < 0.005 
significantly different from the control group by Fisher's PLSD test. 
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Discussion 
Our present results are consistent with a number of 
reports 12,l4,lS,l6 showing that vigabatrin and 
phenobarbitone alone produced a release of the 
suppressed behaviour induced by the aversive 
stimuli of the open arms in the elevated plus-maze 
model of anxiety, as indicated by the increase in 
time spent and in the number of entries into open 
arms of the maze. Recently, the elevated plus-maze 
test and open-field behaviour have extensively been 
used to investigate the exploratory behaviour in 
rodents22. The role of GABA in anxiety has been 
suggested by findings that anxiolytics agents such 
as the benzodiazepines and barbiturates bind to 
specific recognition sites on the GABA-chloride 
complex (see Introduction). Because barbiturates 
and GABA-T inhibitors act postsynaptically to 
enhance GABA-ergic neurotransmission, cross 
generalization between these classes can be taken 
as evidence that GABA-ergic mechanisms are 
involved in the transduction of their anxiolytic and 
exploratory behaviour. However, the major finding 
presented in this study was that pre-treatment of 
rats with vigabatrin abolished the anxiolytic action 
of phenobarbitone sodium in the elevated plus-
maze model of anxiety (Table I) and the increased 
locomotor activity in the open-field test (Figs 1 and 
2). The anxiolytic effect of vigabatrin has also 
disappeared in phenobarbitone-treated rats. This 
behavioural result suggests that another 
neurotransmitter system may be involved or GABA 
has a dual effect against anxiety and exploratory 
behaviour. At low levels of GABA-ergic activity 
(under the effect of either vigabatrin or 
phenobarbitone) GABA would inhibit the 
anxiogenic pathways, while at high levels of the 
activity (under the effect of combined treatment), 
GABA inhibits anxiogenic and anxiolytic pathways 
in the brain resulting in masking of the anxiolytic 
effects. Previously, indirect role of GABA in anxiety 
byinhibitingthe anxiogenicnoradrenergic pathway 
to the locus coeruleus and serotonergic neurons in 
the dorsal raphe has also been suggested23. It is 
possible, therefore, that the dual effect of GABA 
reported in this study might have come from a non-
specific effect of GABA. 
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